secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2021-09-15T23:59:59+00:00
Accession:  0001764013-21-000098
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant appoints Renee Barnett as CFO; shareholders approve option repricing
-------------------------------------------------------------------------------

- Renee Barnett appointed CFO effective Oct 4, 2021; base salary $400K, signing bonus $500K, RSU bonus grant of 59,500 shares vesting Jan 1, 2022.
- Barnett also receives options for 333,000 shares and RSUs for 143,000 shares vesting over four years.
- Annual meeting results: 3 directors elected, EY ratified as auditor, say-on-pay frequency every year approved.
- Stockholders approved repricing of certain outstanding stock options under 2019 Equity Incentive Plan.
- Company plans to initiate pivotal MG trial and reinitiate TED and WAIHA programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/0001764013-21-000098-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401321000098/imvt-20210909.htm
  HTML page:      https://secwatch.observer/filing/0001764013-21-000098

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer